PHOSPHOTENSIN TUMOUR SUPPRESSOR GENE (PTEN) EXPRESSION PATTERNS IN ENDOMETRIAL HYPERPLASIAS AND ENDOMETRIOID CARCINOMA.

Corresponding Author:
Sithara S,
Resident,
Department of Pathology,
Government Medical College,
Kottayam, Kerala, India.
E-mail: sitharashoukkath@gmail.com

ABSTRACT

BACKGROUND

Endometrioid Endometrial Carcinoma (EECA) has been postulated to develop from premalignant lesions like endometrial hyperplasia without atypia, to endometrial hyperplasia with atypia.Various studies have shown PTEN tumour suppressor gene mutation in endometrioid carcinoma and its precursors. Thus, immunohistochemical expression of PTEN may provide a valuable insight into the category of hyperplasia which can be most definitely classified as “premalignant”. This study evaluated PTEN expression in endometrial hyperplasia with and without atypia and endometrioid carcinoma.

MATERIALS AND METHODS

The present study evaluated PTEN expression in endometrial hyperplasia with and without atypia and endometrioid carcinoma in endometrial curetting and hysterectomy specimens received in Government Medical College, Kottayam from 18/4/2017- 9/9/18.

RESULTS

The mean age of study population was 56.98±10.67 years. PTEN is strongly immunoreactive in all cases of proliferative and secretory phase. There was 100% positivity or 0% negativity in endometrial hyperplasia without atypia. In 37% cases of endometrial hyperplasia with atypia and 61% cases of endometrioid carcinoma, there was complete loss of PTEN expression.

CONCLUSION

Loss of PTEN expression is partially associated with endometrioid endometrial cancers via a premalignant phase.

KEY WORDS

PTEN (Phosphotensin Tumour Suppressor Gene); Endometrial Hyperplasia; Endometrioid Carcinoma; Immunohistochemistry.